Hospitalisation days in patients with lung cancer in a general population

Respiratory Medicine

Volumn 103, Issue 12, 2009, Pages 1941-1948

  Skaug, Knut ^a,c   Eide, Geir Egil ^b,c   Gulsvik, Amund ^c  

^a HAUGESUND HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Hospitalisation; Lung cancer; Population

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DYSPNEA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INSTITUTIONAL CARE; LENGTH OF STAY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NORWAY; NURSING HOME; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL TIME; TERMINAL CARE;

ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NORWAY; YOUNG ADULT;

EID: 70350724290     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.05.016     Document Type: Article

References (25)

1. Møller BAB. Cancer incidence, mortality, survival and prevalence in Norway. Yearly report 2005 from Cancer Registry of Norway included special issue 2006(Yearly report 2005 from Cancer Registry of Norway included special issue).
2. Bergman B., and Sorenson S. Hospitalization during chemotherapy for small cell lung cancer. Acta Oncol 29 8 (1990) 977-982
3. Molinier L., Combescure C., Chouaid C., Daures J.P., Housset B., Fabre D., et al. Cost of lung cancer: a methodological review. Pharmacoeconomics 24 7 (2006) 651-659
4. Chouaid C., Molinier L., Combescure C., Daures J.P., Housset B., and Vergnenegre A. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 90 2 (2004) 397-402
5. Chang S., Long S.R., Kutikova L., Bowman L., Finley D., Crown W.H., et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 22 17 (2004) 3524-3530
6. Bordeleau L., and Goodwin P.J. Economic issues in lung cancer. Semin Respir Crit Care Med 21 5 (2000) 375-384
7. Wolstenholme J.L., and Whynes D.K. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 80 1-2 (1999) 215-218
8. WHO. WHO handbook for reporting results of cancer treatment. WHO Offset Publication no. 48 (1979), World Health Organization, Geneva
9. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 6 (1997) 1710-1717
10. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 282 (1958) 457-481
11. Mantel. Evaluation of survival data and two new rank order statistics arising in its concideration. Cancer Chemother Rep 50 (1966) 113-170
12. Cox D.R. Regression models and Life-Tables. J R Stat Soc (1971) 187-202
13. Oliver E., Killen J., Kiebert G., Hutton J., Hall R., Higgins B., et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 56 10 (2001) 785-790
14. Silvestri G.A., Sherman C., Williams T., Leong S.S., Flume P., and Turrisi A. Caring for the dying patient with lung cancer. Chest 122 3 (2002) 1028-1036
15. Strand T.E., Rostad H., Moller B., and Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 61 8 (2006) 710-715
16. Schneider N., Dreier M., Amelung V.E., and Buser K. Hospital stay frequency and duration of patients with advanced cancer diseases- differences between the most frequent tumour diagnoses: a secondary data analysis. Eur J Cancer Care (Engl) 16 2 (2007) 172-177
17. Skaug K., Eide G.E., and Gulsvik A. Prevalence and predictors of symptoms in the terminal stage of lung cancer: a community study. Chest 131 2 (2007) 389-394
18. Braud A.C., Levy-Piedbois C., Piedbois P., Piedbois Y., Livartovski A., Le Vu B., et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 21 9 (2003) 671-679
19. Guest J.F., Ruiz F.J., Greener M.J., and Trotman I.F. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care (Engl) 15 1 (2006) 65-73
20. Dedes K.J., Szucs T.D., Bodis S., Joerger M., Lowy A., Russi E.W., et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 22 7 (2004) 435-444
21. Pimentel F.L., Bhalla S., Laranjeira L., and Guerreiro M. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 52 3 (2006) 365-371
22. von Plessen C., Bergman B., Andresen O., Bremnes R.M., Sundstrom S., Gilleryd M., et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95 8 (2006) 966-973
23. Helbekkmo N., Sundstrom S.H., Aasebo U., Brunsvig P.F., von Plessen C., Hjelde H.H., et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97 3 (2007) 283-289
24. Kutikova L., Bowman L., Chang S., Long S.R., Obasaju C., and Crown W.H. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50 2 (2005) 143-154
25. Fleming I., Monaghan P., Gavin A., and O'Neill C. Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Health Econ 9 1 (2008) 79-86 Epub 2007